NCT05840107 2024-02-13
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
Clinical Trials
25 trialsNCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT04211259 2023-08-07
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Unknown
NCT05655676 2022-12-19
89Zr-labeled NY008 PET Imaging in Patients
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1 Unknown
NCT05652530 2022-12-15
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05016778 2022-11-01
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05478343 2022-07-28
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05430945 2022-06-24
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05364177 2022-05-06
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT05008536 2021-11-23
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04617704 2021-09-22
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04236011 2021-06-15
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT04637269 2020-11-19
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04412889 2020-06-02
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT03436342 2019-12-27
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04186052 2019-12-04
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04182581 2019-12-02
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Xijing Hospital
Phase EARLY_PHASE1 Unknown
NCT04156269 2019-11-12
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT03661554 2018-09-10
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase EARLY_PHASE1 Unknown
NCT03559764 2018-06-18
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02109861 2015-12-08
Phase-0-MM
Aalborg University Hospital
Phase EARLY_PHASE1 Unknown